Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis .
In new Neiman Health Policy Institute research, scientists explored the use of artificial intelligence to aid in diagnosing PE on CTPA, with “AI-informed radiologists" scoring high marks.
